GENERAL
Dr Reddy’s Oral Semaglutide Brand Obeda For Type 2 Diabetes Launched
Dr Reddy’s Laboratories has launched its oral semaglutide biosimilar for the treatment of Type 2 diabetes mellitus in India under the brand name Obeda, strengthening its presence in the fast-growing GLP-1 therapy segment. The launch follows the company’s recent generic semaglutide injection launches in India and Canada, positioning Dr Reddy’s as a full-stack player in […]
CW Bureau
·
May 20, 2026
GENERAL
Dr Reddy’s Taps Canada’s Diabetes Market With Semaglutide Injection
Dr Reddy’s Laboratories (DRL)has launched its generic Semaglutide injection in Canada, becoming among the first companies to introduce the product in the Canadian market following regulatory approval from Health Canada. The company said it received the Notice of Compliance (NOC) from Health Canada on April 28, 2026, paving the way for the commercial launch. Canada […]
CW Bureau
·
May 16, 2026
GENERAL
Dr Reddy’s Launches Semaglutide Generic Injection For Diabetes Care
Dr Reddy’s Laboratories has announced the launch of Obeda, its injectable Semaglutide, marking a significant milestone in expanding access to advanced GLP-1 receptor agonist therapies for the treatment of type 2 diabetes in India. The company claimed that it is the first Indian player to secure approval from the Drugs Controller General of India (DCGI) […]
CW Bureau
·
Mar 21, 2026
